This website is intended for healthcare professionals only

Comprehensive Anatomical Render Of Breast Cancer In A Human Female

Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer

Saumya Easaw, Antoinette R Tan, Arielle L Heeke

Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential for minimal residual disease (MRD) detection and recurrence monitoring. In metastatic breast cancer (MBC), ctDNA […]

touchREVIEWS in Oncology & Haematology. 2026;22(2):1–4:Online ahead of journal publication

Hematologic Malignancies Leukemia

Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial

5 mins

Published Online: Jan 5th 2023

Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses the results from a recent clinical trial that were presented at ASH 2022. Abstract 2757: ‘Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial‘

Disclosures: Jorge Cortes is a consultant for Novartis, Pfizer, Takeda, Sun Pharma and Rigel. He has received grant/research support from Novartis and Sun Pharma, and is on the advisory board for Novartis.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 64th ASH Annual Meeting & Exposition

Access more Leukaemia content here

Focus on leukemia – Felix and ASC4FIRST

Elias Jabbour

The open-label, single-arm phase Ib/II Felix study (NCT04404660) investigated obecabtagene autoleucel (obe-cel, AUTO1), a novel anti-CD19 autologous CAR-T cell therapy, in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. The results suggest that obe-cel can provide long-term remission without necessarily needing a transplant. touchONCOLOGY spoke with editorial board member, Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA), who summarized the key take-home messages from his presentation at ASCO 2024. Dr Jabbour also discussed the findings from the ASC4FIRST trial (NCT04971226).

Related Videos in Leukemia

Developed by Touch

Robin Foà, EHA 2023: José Carreras Award presentation - research on Philadelphia-positive acute lymphoblastic leukaemia

Each year, the EHA Board presents the José Carreras Award to honour leaders in haematological research. touchONCOLOGY caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss his receipt of the José Carreras Award and the key take-home ...

Developed by Touch

Robin Foà, EHA 2023: New developments in the treatment of Philadelphia-positive acute lymphoblastic leukaemia

The management of patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) has evolved over the last few decades, with new and exciting treatments becoming increasingly available. We caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss the ...

Developed by Touch

Arnon Kater, EHA 2023: MURANO substudy analysis: Venetoclax-rituximab in patients with chronic lymphocytic leukaemia

The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic ...

Developed by Touch

Elias Jabbour, ASCO 2023: PhALLCON: A phase 3 study comparing ponatinib vs imatinib patients with Ph+ALL

The randomized phase 3 PhALLCON trial was conducted in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. The practice-changing efficacy results and safety data demonstrate a potential for a new standard-of-care therapy for frontline use in this patient population and improvements ...

Developed by Touch

Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study

The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with ...

Developed by Touch

Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib

Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with ...

Developed by Touch

Jorge Cortes, ASH 2022: Advances in triplet therapy for relapsed or refractory acute myeloid leukaemia

Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses some of the most interesting abstracts presented at the recent ASH 2022 congress that show advances in triplet therapy for relapsed or refractory acute myeloid leukaemia. Abstracts discussed: Abstract 61: 'Phase I/II ...

Developed by Touch

Jorge Cortes, ASH 2022: New agents in relapsed or refractory acute myeloid leukaemia

Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses his highlights from the recent ASH 2022 conference, including two new agents that look promising in early studies on patients with relapsed or refractory acute myeloid leukaemia. Abstracts discussed: Abstract 63: 'The Menin ...

Developed by Touch

John Mascarenhas, ASH 2022: Pacritinib for the treatment of myelofibrosis and severe thrombocytopenia, the PACIFICA study

The PACIFICA study aimed to assess the efficacy and safety of pacritinib versus physician's choice therapy in patients with myelofibrosis and severe thrombocytopenia. In this touchONCOLOGY interview, we speak with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, ...

Developed by Touch

John Mascarenhas, ASH 2022: Treatment challenges in myelofibrosis and severe thrombocytopenia and the rationale for the use of pacritinib

Treatment options for myelofibrosis and severe thrombocytopenia are restricted due to high occurrences of JAK inhibitor-related thrombocytopenia. Pacritinib offers benefits for those patients with cytopenias. In this touchONCOLOGY interview, we speak with Dr John Mascarenhas (Icahn School of Medicine at ...

Developed by Touch

Jennifer Brown, ASH 2022: Zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma, ALPINE (phase III) results

The ALPINE study in patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma has shown that zanubrutinib may offer potential advantages over ibrutinib. In this touchONCOLOGY interview, we speak with Dr Jennifer Brown (Dana-Farber Cancer Institute, Boston, MA, ...

Developed by Touch

Mark Litzow, ASH 2022: Relapse rates, prognosis and blinatumomab approval status in patients with acute lymphoblastic leukaemia

Complete remission rates are high for adults with acute lymphoblastic leukaemia (ALL), however, relapse is frequent and survival rates are poor even if the measurable residual disease (MRD) status is negative. In this touchONCOLOGY interview, we speak with Dr Mark ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer

Learning Activities

Congress Highlights

Journals

Specialities

Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer

Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial

Register now for
FREE access

Focus on leukemia – Felix and ASC4FIRST

Robin Foà, EHA 2023: José Carreras Award presentation - research on Philadelphia-positive acute lymphoblastic leukaemia

Robin Foà, EHA 2023: New developments in the treatment of Philadelphia-positive acute lymphoblastic leukaemia

Arnon Kater, EHA 2023: MURANO substudy analysis: Venetoclax-rituximab in patients with chronic lymphocytic leukaemia

Elias Jabbour, ASCO 2023: PhALLCON: A phase 3 study comparing ponatinib vs imatinib patients with Ph+ALL

Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study

Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib

Jorge Cortes, ASH 2022: Advances in triplet therapy for relapsed or refractory acute myeloid leukaemia

Jorge Cortes, ASH 2022: New agents in relapsed or refractory acute myeloid leukaemia

John Mascarenhas, ASH 2022: Pacritinib for the treatment of myelofibrosis and severe thrombocytopenia, the PACIFICA study

John Mascarenhas, ASH 2022: Treatment challenges in myelofibrosis and severe thrombocytopenia and the rationale for the use of pacritinib

Jennifer Brown, ASH 2022: Zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma, ALPINE (phase III) results

Mark Litzow, ASH 2022: Relapse rates, prognosis and blinatumomab approval status in patients with acute lymphoblastic leukaemia

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Congress Highlights

Trending Topic

Connect With Us:

Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial

Register now forFREE access

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

Register now for FREE access

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Register now for
FREE access